These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31886602)

  • 21. Statistical design and analysis in trials of proportionate interventions: a systematic review.
    Candlish J; Teare MD; Cohen J; Bywater T
    Trials; 2019 Feb; 20(1):151. PubMed ID: 30819224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A response-adaptive randomization procedure for multi-armed clinical trials with normally distributed outcomes.
    Williamson SF; Villar SS
    Biometrics; 2020 Mar; 76(1):197-209. PubMed ID: 31322732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Test Statistics and Confidence Intervals to Establish Noninferiority between Treatments with Ordinal Categorical Data.
    Zhang F; Miyaoka E; Huang F; Tanaka Y
    J Biopharm Stat; 2015; 25(5):921-38. PubMed ID: 24919157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familywise error control in multi-armed response-adaptive two-stage designs.
    Gutjahr G; Posch M; Brannath W
    J Biopharm Stat; 2011 Jul; 21(4):818-30. PubMed ID: 21516571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A free gift: an adaptive strategy in a single-arm trial using an exact test through the binomial distribution.
    Wang J
    J Biopharm Stat; 2012; 22(6):1127-36. PubMed ID: 23075012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
    Huang B; Talukder E; Han L; Kuan PF
    J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis strategies for adaptive designs with multiple endpoints.
    Chang M; Chow SC
    J Biopharm Stat; 2007; 17(6):1189-200. PubMed ID: 18027225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analyzing multiple endpoints in a confirmatory randomized clinical trial-an approach that addresses stratification, missing values, baseline imbalance and multiplicity for strictly ordinal outcomes.
    Sun H; Kawaguchi A; Koch G
    Pharm Stat; 2017 Mar; 16(2):157-166. PubMed ID: 28074600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2041-54. PubMed ID: 22733687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multistage analysis strategy for a clinical trial to assess successively more stringent criteria for a primary endpoint with a low event rate.
    Li S; Hussey MA; Schwartz TA; Koch GG
    Pharm Stat; 2013; 12(2):65-73. PubMed ID: 23424092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An entropy-based nonparametric test for the validation of surrogate endpoints.
    Miao X; Wang YC; Gangopadhyay A
    Stat Med; 2012 Jun; 31(14):1517-30. PubMed ID: 22344829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptive design and estimation in randomized clinical trials with correlated observations.
    Yin G; Shen Y
    Biometrics; 2005 Jun; 61(2):362-9. PubMed ID: 16011682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adaptive clinical endpoint bioequivalence studies with sample size re-estimation based on a nuisance parameter.
    Zhu L; Sun W
    J Biopharm Stat; 2019; 29(5):776-799. PubMed ID: 31505986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global rank tests for multiple, possibly censored, outcomes.
    Ramchandani R; Schoenfeld DA; Finkelstein DM
    Biometrics; 2016 Sep; 72(3):926-35. PubMed ID: 26812695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controlling the family-wise error rate in multi-arm, multi-stage trials.
    Crouch LA; Dodd LE; Proschan MA
    Clin Trials; 2017 Jun; 14(3):237-245. PubMed ID: 28545335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup.
    Sugitani T; Posch M; Bretz F; Koenig F
    Stat Med; 2018 Oct; 37(24):3387-3402. PubMed ID: 29945304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flexible designs by adaptive plans of generalized Pocock- and O'Brien-Fleming-type and by self-designing clinical trials.
    Hartung J
    Biom J; 2006 Aug; 48(4):521-36. PubMed ID: 16972703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.